


CEPI – Coalition for Epidemic Preparedness Innovations



Stopping future epidemics
by developing new vaccines

www.cepi.net




Ebola – The Tipping Point





Ebola: A Wake-Up Call


Global costs of Ebola; a outbreak response



<https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/cost-of-ebola.html>


Ebola: Where Is The Vaccine?

Historic R&D speed and progress




CEPI

Ebola Vaccine Development— Successful, but too late and unfinished



- No licensed vaccine despite 100% VE in one CT, and despite Merck and J&J submitted EUAL to WHO in 2015 and 2016
- No formal regulatory or policy framework
- No credible demand/ stockpile forecasts; decreasing sense of urgency
- “Ebola Team B” - finish the job

Ebola – The Tipping Point Need for a global synchronised solution - CEPI



CEPI's First Investors

Investor	Amount
Norway	\$120,000,000
Japan	\$125,000,000
Germany	\$95,000,000
Bill&Melinda Gates Foundation	\$100,000,000
Wellcome Trust	\$100,000,000
In addition: EC plans to co-fund with €250 mill	

CEPI

What Is CEPI?

- CEPI is a partnership of public, private, philanthropic and civil society organisations
- CEPI will *stimulate, finance and coordinate* vaccine development
 - against priority threats,
 - particularly when development is unlikely to occur through market incentives alone.
 - Focuses investment in late stage preclinical to clinical proof of concept for human vaccines

CEPI

Diseases With Public Health Emergency Potential

WHO	NIPH
<ul style="list-style-type: none"> Arenaviral haemorrhagic fevers (incl Lassa Fever) Crimean-Congo Haemorrhagic Fever Filovirus diseases (incl Ebola & Marburg) Middle East Respiratory Highly Syndrome Coronavirus (MERS Co-V) Other highly pathogenic coronaviral diseases (such as SARS) Nipah and related henipaviral diseases Rift Valley Fever Severe fever with thrombocytopenia syndrome SFTS Zika Disease "X" (Chikungunya) 	<ul style="list-style-type: none"> Ebolavirus Hepatitis C virus Enterovirus 71 West Nile virus Chikungunya virus Marburg virus Yersinia pestis Rift valley fever virus SARS-CoV MERS-CoV Lassa virus Nipah virus Coxsackievirus A16 Crimean-Congo haemorrhagic fever virus SFTS virus Zika virus Enterovirus 68



centre Publications Countries Programmes Governance About WHO

Emergencies preparedness, response

2017

2016 | Previous years

- 9 May 2017 Human infection with avian influenza A(H7N9) virus – China
- 5 May 2017 Unexplained cluster of deaths – Liberia
- 5 May 2017 Hepatitis E – Niger
- 1 May 2017 Human infection with avian influenza A(H7N9) virus – China
- 27 April 2017 Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia and Qatar
- 24 April 2017 Middle East respiratory syndrome coronavirus (MERS-CoV) – United Arab Emirates
- 20 April 2017 Human infection with avian influenza A(H7N9) virus – China



CEPI's Initial Target Diseases

Call for proposal for human vaccines



DISEASES TO BE URGENTLY ADDRESSED UNDER THE R&D BLUEPRINT, AS OF MAY 2016



Disease selection criteria

- WHO R&D Blueprint
- Public health impact
- Risk of human-human transmission
- Risk of outbreaks
- Feasibility of vaccine development

CEPI's Immediate Agenda

Calls for proposals/ information

1. MERS, Lassa-fever and Nipah Virus Vaccines

2. Vaccine Platform Technologies

3. Ebola – finish the job

CEPI Success Criteria by 2021

- 4-6 vaccines against ≥ 2 priority diseases moved from preclinical to POC/ EUAL/ phase III readiness
- Industry partnership established to ensure manufacturing capacity
- Technical and institutional platforms for rapid response R&D, clinical evaluation and manufacturing capabilities are established
- Ensure regulatory pathways adequacy and use; support strategy for late clinical development and stockpiling

CEPI


CfP MERS, Lassa, Nipah

Status of call

- January 17: call launched
- March: deadline for first round of proposals
 - 28 eligible proposals (4 Nipah, 11 MERS, 11 Lassa, 2 multi-diseases)
 - Applications from all regions except Latin America
 - 3 proposals from German companies as primary applicant and 6 as consortium partner
 - Wide diversity in applicants: Academia, Biotech's, MNCs, Product Development Partnerships.
- Next steps: shortlisting of proposals (summer), due diligence
- Final awards: end 2017

CEPI

CEPI/BMGF Joint CFI Rapid response platform technologies



- 56 submissions for rapid response vaccines platforms
 - In 5 submissions German companies primary applicant
- More than 20 different technology platforms
- Information will shape the final CFP planned for summer

CEPI: Summary And Outlook

- CEPI is
 - An independent non-for-profit organization set up and funded by a variety of governmental and non-governmental stakeholders
 - Its role is to facilitate/ fund late stage development of human vaccines against pathogens with epidemic/pandemic outbreak potential and of rapid response technology platforms
- What we can expect from CEPI
 - Various vaccines with POC and various validated technology platforms by 2021
 - Focused activities around Ebola to “finish the job”, short-term
- What we can NOT expect from CEPI
 - Any impact already on epidemics/ pandemics occurring near-term

CEPI